Taishi Harada

3.8k total citations · 1 hit paper
114 papers, 2.6k citations indexed

About

Taishi Harada is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Taishi Harada has authored 114 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 71 papers in Oncology, 70 papers in Pulmonary and Respiratory Medicine and 25 papers in Molecular Biology. Recurrent topics in Taishi Harada's work include Lung Cancer Treatments and Mutations (52 papers), Lung Cancer Research Studies (33 papers) and Lung Cancer Diagnosis and Treatment (12 papers). Taishi Harada is often cited by papers focused on Lung Cancer Treatments and Mutations (52 papers), Lung Cancer Research Studies (33 papers) and Lung Cancer Diagnosis and Treatment (12 papers). Taishi Harada collaborates with scholars based in Japan, United States and Australia. Taishi Harada's co-authors include Yoichi Nakanishi, Koichi Takayama, Eiji Iwama, Isamu Okamoto, Morimasa Wada, Michihiko Kuwano, Kazuto Furuyama, Keiichi Ota, Kyoko Okamura and Koichi Azuma and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Taishi Harada

109 papers receiving 2.6k citations

Hit Papers

Induction of PD-L1 Expres... 2015 2026 2018 2022 2015 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Induction of PD-L1 Expression by the EML4–ALK Oncoprotein and Downstream Signaling Pathways in Non–Small Cell Lung Cancer
    2015 366 citations Keiichi Ota, Koichi Azuma et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Taishi Harada Japan 27 1.5k 1.4k 855 316 219 114 2.6k
Guanghui Gao China 30 1.5k 1.0× 1.4k 1.0× 811 0.9× 620 2.0× 170 0.8× 86 2.5k
Geon Kook Lee South Korea 30 900 0.6× 1.1k 0.8× 866 1.0× 607 1.9× 249 1.1× 93 2.6k
Sergey Orlov Russia 21 867 0.6× 1.0k 0.8× 804 0.9× 293 0.9× 181 0.8× 149 2.0k
Alessandra Fabbri Italy 21 1.0k 0.7× 744 0.5× 622 0.7× 369 1.2× 71 0.3× 64 2.1k
Shigeki Umemura Japan 24 1.2k 0.8× 841 0.6× 633 0.7× 245 0.8× 89 0.4× 112 2.0k
Mishie Tanino Japan 25 533 0.4× 650 0.5× 961 1.1× 497 1.6× 283 1.3× 117 2.3k
Iwao Mikami Japan 28 801 0.5× 1.0k 0.7× 1.9k 2.3× 303 1.0× 156 0.7× 86 3.1k
Fan Jin United States 23 1.2k 0.8× 518 0.4× 657 0.8× 334 1.1× 240 1.1× 75 2.2k
Dingwei Ye China 28 698 0.5× 1.1k 0.8× 1.6k 1.9× 750 2.4× 234 1.1× 151 3.2k
Edurne Arriola Spain 27 1.4k 0.9× 931 0.7× 662 0.8× 604 1.9× 222 1.0× 122 2.3k

Countries citing papers authored by Taishi Harada

Since Specialization
Citations

This map shows the geographic impact of Taishi Harada's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Taishi Harada with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Taishi Harada more than expected).

Fields of papers citing papers by Taishi Harada

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Taishi Harada. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Taishi Harada. The network helps show where Taishi Harada may publish in the future.

Co-authorship network of co-authors of Taishi Harada

This figure shows the co-authorship network connecting the top 25 collaborators of Taishi Harada. A scholar is included among the top collaborators of Taishi Harada based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Taishi Harada. Taishi Harada is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Oka, Kohei, et al.. (2024). Intrathecal Trastuzumab for HER2-Positive Cancer of Unknown Primary Leptomeningeal Metastasis: A Case Report. Cureus. 16(3). e57322–e57322. 1 indexed citations
2.
Katayama, Yuki, Tadaaki Yamada, Ryo Sawada, et al.. (2024). Prospective Observational Study of Ramucirumab Plus Docetaxel After Combined Chemoimmunotherapy in Patients With Non-Small-Cell Lung Cancer. The Oncologist. 29(5). e681–e689. 1 indexed citations
3.
Katayama, Yuki, Tadaaki Yamada, Kenji Morimoto, et al.. (2024). CYFRA 21-1 predicts efficacy of combined chemoimmunotherapy in patients with advanced non-small cell lung cancer: a prospective observational study. Translational Lung Cancer Research. 13(8). 1929–1937. 1 indexed citations
4.
5.
6.
Katayama, Yuki, Tadaaki Yamada, Kenji Morimoto, et al.. (2023). TTF-1 Expression and Clinical Outcomes of Combined Chemoimmunotherapy in Patients With Advanced Lung Adenocarcinoma: A Prospective Observational Study. JTO Clinical and Research Reports. 4(4). 100494–100494. 5 indexed citations
7.
8.
Ijichi, Kayo, et al.. (2022). Advanced atypical lung carcinoid tumour successfully treated with carboplatin, etoposide and atezolizumab: A case report. SHILAP Revista de lepidopterología. 10(5). e0951–e0951. 5 indexed citations
9.
Morimoto, Kenji, Ryo Sawada, Tadaaki Yamada, et al.. (2022). A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With EGFR-Mutant NSCLC. JTO Clinical and Research Reports. 3(9). 100388–100388. 5 indexed citations
10.
Morimoto, Kenji, Tadaaki Yamada, Tadaaki Yamada, et al.. (2022). Efficacy and Safety of Programmed Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC: A Prospective Observational Study. JTO Clinical and Research Reports. 3(7). 100353–100353. 7 indexed citations
11.
Iwai, N., Takashi Okuda, Taishi Harada, et al.. (2020). Gastric Metastasis from Colorectal Cancer Mimicking a Submucosal Tumor. Case Reports in Gastroenterology. 14(2). 338–345. 4 indexed citations
12.
Yamada, Tadaaki, Yuki Katayama, Akihiro Yoshimura, et al.. (2019). Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR‐mutated non‐small cell lung cancer. Cancer Medicine. 8(4). 1521–1529. 78 indexed citations
13.
Ota, Keiichi, Yoshimasa Shiraishi, Taishi Harada, et al.. (2017). OA08.02 Phase II Study of Erlotinib in Advanced Non-Small Cell Lung Cancer Patients with Leptomeningeal Metastasis (LOGIK1101). Journal of Thoracic Oncology. 12(1). S271–S272. 10 indexed citations
14.
Ota, Keiichi, Koichi Azuma, Akihiko Kawahara, et al.. (2015). Induction of PD-L1 Expression by the EML4–ALK Oncoprotein and Downstream Signaling Pathways in Non–Small Cell Lung Cancer. Clinical Cancer Research. 21(17). 4014–4021. 366 indexed citations breakdown →
15.
Li, Heyan, Shuo Wang, Koichi Takayama, et al.. (2015). Nicotine induces resistance to erlotinib via cross-talk between α 1 nAChR and EGFR in the non-small cell lung cancer xenograft model. Lung Cancer. 88(1). 1–8. 32 indexed citations
16.
Furuyama, Kazuto, Taishi Harada, Eiji Iwama, et al.. (2013). Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR‐tyrosine kinase inhibitors. Cancer Science. 104(5). 584–589. 43 indexed citations
17.
Harada, Taishi, Yasushi Yatabe, Masafumi Takeshita, et al.. (2011). Role and Relevance of TrkB Mutations and Expression in Non–Small Cell Lung Cancer. Clinical Cancer Research. 17(9). 2638–2645. 47 indexed citations
18.
Takayama, Koichi, Miiru Izumi, Taishi Harada, et al.. (2008). Immunohistochemical expression of MRP2 and clinical resistance to platinum-based chemotherapy in small cell lung cancer.. PubMed. 27(6C). 4351–8. 24 indexed citations
19.
Tada, Yasuhiro, Morimasa Wada, Kentaro Kuroiwa, et al.. (2000). MDR1 gene overexpression and altered degree of methylation at the promoter region in bladder cancer during chemotherapeutic treatment.. PubMed. 6(12). 4618–27. 94 indexed citations
20.
Nishioka, Mikio, et al.. (1978). [Cell-mediated immune response in patients with chronic liver diseases (author's transl)].. PubMed. 75(5). 656–63. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Guanghui Gao Breakdown of academic impact, for papers by Geon Kook Lee Breakdown of academic impact, for papers by Sergey Orlov Breakdown of academic impact, for papers by Alessandra Fabbri Breakdown of academic impact, for papers by Shigeki Umemura Breakdown of academic impact, for papers by Mishie Tanino Breakdown of academic impact, for papers by Iwao Mikami Breakdown of academic impact, for papers by Fan Jin Breakdown of academic impact, for papers by Dingwei Ye Breakdown of academic impact, for papers by Edurne Arriola
Rankless by CCL
2026